EGFR and lung carcinoma: The recent discovery of lung cancer mutations in the EGFR kinase domain [35]–[37] and their differential sensitivity to EGFR inhibitors have suggested that genetic alterations may be associated with structural changes, rendering tumors sensitive to selective inhibitors.